This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

KRAS Inhibitors, Novel Targeted TKIs, Checkpoint Inhibitors: Where is the lung cancer treatment market heading as we approach ESMO 2019 and important data readouts in the 4th Quarter?


Who's the expert?

Name: Dr Rafael Santana-Davila - MD

Institution: University of Washington

  • Assistant Professor, University of Washington School of Medicine & medical oncologist at Seattle Cancer Care Alliance who specializes in treating lung and head and neck cancers.
  • Manages 400 patients (total) with lung cancer, 30 patients with HNSCC and 30 patients with SCLC each month.
  • Has been involved in numerous lung cancer clinical trials and research focuses on designing and implementing clinical trials that test new treatments in the battle against cancer.

Interview Goal
This call will focus on preparing for Amgen's AMG 510 ESMO data and KOL expectations. Adam will also focus on the expectations for Mirati's KRAS inhibitor, which will readout first data in Q4.
The second focus of the conversation will be on TKIs and Checkpoint Inhibitors. This portion will focus on: 
  1. Gaining insight into novel lung cancer targets.
  2. Discuss Keytruda's current lock on checkpoints in lung and whether AstraZeneca or Roche have a chance of stepping up.

Are You Interested In These Questions?

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.